PMV Pharmaceuticals (NASDAQ:PMVP) vs. Amarillo Biosciences (OTCMKTS:AMAR) Head-To-Head Contrast

Amarillo Biosciences (OTCMKTS:AMAR) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, analyst recommendations and valuation.

Volatility & Risk

Amarillo Biosciences has a beta of -0.06, suggesting that its stock price is 106% less volatile than the S&P 500. Comparatively, PMV Pharmaceuticals has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Amarillo Biosciences and PMV Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarillo Biosciences	0	0	0	0	N/A
PMV Pharmaceuticals	0	0	4	1	3.20

PMV Pharmaceuticals has a consensus target price of $5.75, suggesting a potential upside of 285.91%.

Valuation & Earnings

This table compares Amarillo Biosciences and PMV Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarillo Biosciences	$20,000.00	0.00	-$1.45 million	N/A	N/A
PMV Pharmaceuticals	N/A	N/A	-$68.96 million	($1.33)	-1.12

Amarillo Biosciences has higher revenue and earnings than PMV Pharmaceuticals.

Institutional and Insider Ownership

90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 34.4% of Amarillo Biosciences shares are owned by insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Amarillo Biosciences and PMV Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amarillo Biosciences	-41,453.98%	N/A	-574.29%
PMV Pharmaceuticals	N/A	-21.96%	-19.80%

Summary

PMV Pharmaceuticals beats Amarillo Biosciences on 6 of the 10 factors compared between the two stocks.

About Amarillo Biosciences

Amarillo Biosciences, Inc., a healthcare company, engages in the discovery and development of pharmaceutical and biotech products in the United States and Asia. The company operates in three divisions: Pharmaceutical, Medical, and Consumer. The Pharmaceutical division offers low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Medical division focuses on medical devices and developing technology to treat metabolism related diseases, such as Type 1 and Type 2 diabetes. The Consumer division provides a range of nutraceutical and food supplement products that utilize a liposomal delivery system. It owns four issued patents related to the low-dose oral delivery of interferon; one patent is for a product promoting oral health; and three patents are associated with treatment of metabolic disorders. The company was incorporated in 1984 and is based in Amarillo, Texas.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.